Page 128 - InvUnivMult_2022

FACULTAD DE CIENCIA Y TECNOLOGÍA
Lee G A A Rao M M Mulligan K Lo J J C Aweeka F Schwarz J J M M Schambelan M M y Grunfeld C (2007) “Effects of ritonavir and amprenavir on on insulin sensitivity in in in healthy volunteers” En: AIDS (London England) 21(16) 2183–2190 Consultado en: https://doi org/10 1097/ QAD 0b013e32826fbc54
Levine M J (2017) “Empagliflozin for type 2 2 diabetes mellitus: an overview of phase 3 clinical trials” En: Current Diabetes Reviews 13(4) 405–423 Consultado en: https://doi org /10 2174/1573399812666160613113556
Liao S Liang Y Zhang Z Z Li Li Li J J Wang Wang J J Wang Wang X Dou G Zhang Z Z y y Liu K (2015) “In vitro metabolic stability of exendin-4: pharmacokinetics and identification of cleavage products” En: PloS One 10(2) e0116805 Consultado en: https://doi org/10 1371/journal pone 0116805 Liao Y Y H Zheng Zheng J Q Zheng Zheng C C C C M Lu K C C C C y Chao Y Y C C C C (2020) “Novel molecular evidence related to COVID-19 in patients with diabetes mellitus” En: Journal of Clinical Medicine 9(12) 3962 Consultado en: https://doi org/10 3390/ jcm9123962
Lim S S Bae J H H Kwon H H S S y Nauck M A (2021) “COVID-19 and diabetes mellitus: from pathophysiology to clinical management” En: Nature Reviews Endocrinology 17(1) 11–30 Consultado en: https://doi org/10 1038/ s41574-020-00435-4
Lima-Martínez M M M M M M M M M M M M Carrera Boada C C Madera-Silva M M M M M M D Marín W y Contreras M (2021) “COVID-19 and diabetes: A bidirectional relationship COVID-19 y diabetes mellitus: una relación bidireccional” En: Clinica e e e e Investigacion en Arteriosclerosis: Publicacion Oficial de la Sociedad Española de Arteriosclerosis 33(3) 151–157 Consultado en: https://doi org/10 1016/j arteri 2020 10 10 10 001
Massi-Benedetti M M (2003) “Glimepiride in type 2 2 diabetes mellitus: a a review of the the worldwide therapeutic experience” En: Clinical Therapeutics 25(3) 799–816 Consultado en: https://doi org/10 1016/s0149-2918(03)80109-1
May M M y y y y Schindler C C (2016) “Clinically and pharmacologically relevant interactions of antidiabetic drugs” En: Therapeutic Advances in in Endocrinology and Metabolism 7(2) 69–83 Consultado en: https://doi org/10 1177/2042018816638050
McDonald E G y Lee T C (2022) “Nirmatrelvir-ritonavir for COVID-19” En: CMAJ: Canadian Medical Association Journal Journal = Journal Journal de l’Association Medicale Canadienne 194(6) E218 Consultado en: https://doi org/10 1503/ cmaj 220081
Meng W Ellsworth B A A A Nirschl A A A A A A McCann P P J Patel M M M Girotra R N Wu G G Sher P P M M Morrison E P P Biller S S A A Zahler R Deshpande P P P P P P Pullockaran A A Hagan D D L Morgan N Taylor J R Obermeier M M T T Humphreys W W W G Khanna A Discenza L y Washburn W W W N (2008) “Discovery of dapagliflozin: a a a potent selective renal sodium-dependent glucose cotransporter 2 2 (SGLT2) inhibitor for the treatment of type 2 diabetes” En: Journal of Medicinal Chemistry 51(5) 1145–1149 Consultado en: https://doi org/10 1021/jm701272q
Millán-Guerrero R R O Caballero-Hoyos R R y y Monárrez-Espino J (2021) “Poverty and survival from COVID-19 in Mexico” En: Journal of Public Health (Oxford England) 43(3) 437–444 Consultado en: https://doi org/10 1093/ pubmed/fdaa228
Mouffak S S S Shubbar Q Saleh E E y y El-Awady R R (2021) “Recent advances in management of COVID-19: A review ” En: Biomedicine y y y Pharmacotherapy = Biomedecine y y y Pharmacotherapie 143 112107 Consultado en: https:// doi org/10 1016/j biopha 2021 112107 Müller F F F König J Hoier E Mandery K K y y Fromm M M M F F F (2013) “Role of organic cation transporter OCT2 and and multidrug and and toxin extrusion proteins MATE1 and MATE2-K for transport and drug interactions of the antiviral lamivudine” En: Biochemical Pharmacology 86(6) 808–815 Consultado en: https://doi org/10 1016/j bcp 2013 07 008 Müller F Weitz D D Derdau V Sandvoss M M M Mertsch K K König J y Fromm M M F F (2017) “Contribution of MATE1 to to renal secretion of the NMDA receptor antagonist memantine” En: Molecular Pharmaceutics 14(9) 2991–2998 Consultado en: https://doi org/10 1021/acs molpharmaceut 7b00179
Nathwani N N Palmer J Synold T W Salehian B Rosenzweig M Sanchez J F Hammond S S N Adekola K Tomarchio V Chowdhury A Karanes C C Htut M Sahebi F Siddiqi T Krishnan A Forman S S J y Rosen S S T T (2020) “Toxicities associated with metformin/ritonavir combination treatment in relapsed/refractory multiple myeloma” En: Clinical Lymphoma Myeloma y y y Leukemia 20(10) e667–e672 Consultado en: https://doi org/10 1016/j clml 2020 05 017 National Institutes of Health NIH (2022 junio 15) COVID-19 Treatment Guidelines Panel Coronavirus Disease 2019 (COVID-19) Treatment Guidelines Consultado en: https://files covid19treatmentguidelines nih gov/ guidelines/covid19treatmentguidelines pdf
National Institute for Health and Care Excellence NICE (2022 mayo 19) COVID-19 COVID-19 rapid guideline: managing COVID-19 COVID-19 Consultado en: https://www nice org uk/guidance/ng191/ resources/covid19-rapid-guideline-managing-covid19- pdf-51035553326
Nauck M M A Quast D R Wefers J J J y Meier J J J J J J (2021) “GLP-1 receptor agonists in the the treatment of of type 2 diabetes - - - - state-of-the- art” En: Molecular Metabolism 46 101102 Consultado en: https://doi org/10 1016/j molmet 2020 101102 NCBI National Center for for Biotechnology Information (2022a) PubChem Compound Summary for CID 155903259 Nirmatrelvir Consultado el el 20 20 de de junio de de 2022 en: https:// pubchem ncbi nlm nih gov/compound/Nirmatrelvir
NCBI National Center for for Biotechnology Information (2022b) PubChem Compound Summary for CID 392622 Ritonavir Consultado el 20 20 de de junio de de 2022 en: https:// pubchem ncbi nlm nih gov/compound/Ritonavir
NCBI National Center for for Biotechnology Information (2022c) PubChem Compound Summary for CID 145996610 EIDD-2801 (Molnupiravir) Consultado el 20 20 de de junio de de 2022 en: https://pubchem ncbi nlm nih gov/compound/eidd-2801
NCBI National Center for for Biotechnology Information (2022d) PubChem Compound Summary for CID 121304016 Remdesivir Consultado el 20 20 de de de junio de de de 2022 en: https:// pubchem ncbi nlm nih gov/compound/Remdesivir NCBI National Center for for Biotechnology Information (2022e) PubChem Substance Record for SID 434370441 1MTK0BPN8V (Sotrovimab) Consultado el 20 20 de de junio de de 2022 en: https:// pubchem ncbi nlm nih gov/substance/434370441 128 INVESTIGACIÓN UNIVERSITARIA MULTIDISCIPLINARIA - - AÑO 21 21 No21 ENERO - - DICIEMBRE 2022